Having trouble accessing articles? Reset your cache.

Tivozanib: Additional Phase II data

Additional data from a placebo-controlled Phase II trial in 272 patients naïve to VEGF therapy showed that once-daily oral tivozanib led to a median

Read the full 244 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE